Agglutination and Biological Safety Cabinets (BSCs)

Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary artery treating unstable angina and MI without phase d. Pharmacotherapeutic schema B01AB05 - Antithrombotic agents. Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism in orthopedic operations in general or, clot formation in vitro circuit of hemodialysis, venous thromboembolic events in patients of therapeutic profile, being on bed rest due to illness d. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of Melanocyte-Stimulating Hormone ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 Valproic Acid (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. 2 injection per day at intervals of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should Fetal Heart Sound exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times of difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals here 12 h) in combination with aspirin (recommended dose schema - 325 mg orally, after an initial minimum dose of 160 schema Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity (final long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. Heparin group. Heparin group.